310 related articles for article (PubMed ID: 32652877)
1. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
2. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
Mei Y; Liao X; Zhu L; Yang H
J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
[TBL] [Abstract][Full Text] [Related]
4. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
Yang L; Tian Y; Leong WS; Song H; Yang W; Wang M; Wang X; Kong J; Shan B; Song Z
Breast Cancer Res; 2018 Sep; 20(1):113. PubMed ID: 30227879
[TBL] [Abstract][Full Text] [Related]
5. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
Wang R; Zhang T; Yang Z; Jiang C; Seng J
J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
[TBL] [Abstract][Full Text] [Related]
7. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
8. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
9. Suppression of Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Potentiates Cell Apoptosis and Drug Sensitivity to Taxanes and Adriamycin in Breast Cancer.
Yu J; Jin T; Zhang T
Med Sci Monit; 2020 Jul; 26():e922672. PubMed ID: 32623440
[TBL] [Abstract][Full Text] [Related]
10. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
Chang L; Hu Z; Zhou Z; Zhang H
Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
[TBL] [Abstract][Full Text] [Related]
11. A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells.
Kim H; Park GS; Lee JE; Kim JH
Br J Cancer; 2013 Jul; 109(2):351-9. PubMed ID: 23799854
[TBL] [Abstract][Full Text] [Related]
12. Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11.
Chen Y; Tang W; Zhu X; Zhang L; Zhu Y; Xiao H; Xu J; Fang Y; Li X; Tang C; Shi J
Bioengineered; 2021 Dec; 12(2):11506-11519. PubMed ID: 34905470
[TBL] [Abstract][Full Text] [Related]
13. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
[TBL] [Abstract][Full Text] [Related]
14. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
17. PA-MSHA inhibits the growth of doxorubicin-resistant MCF-7/ADR human breast cancer cells by downregulating Nrf2/p62.
Wei Y; Liu D; Jin X; Gao P; Wang Q; Zhang J; Zhang N
Cancer Med; 2016 Dec; 5(12):3520-3531. PubMed ID: 27758045
[TBL] [Abstract][Full Text] [Related]
18. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Zang H; Li Y; Zhang X; Huang G
Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
